CORDIS - Forschungsergebnisse der EU
CORDIS
Inhalt archiviert am 2024-05-29

Applied venomics of the cone snail species Conus consors for the accelerated, cheaper, safer and more ethical production of innovative biomedical drugs

Ziel

Venomous animals represent a major source of highly selective and efficient bioactive compounds that have already led to the development of several new drugs. The latest FDA approved example is Prialt, a peptide originating from the venom of a cone snail (Conus magus). CONCO is an innovative post-genomic project dedicated to the discovery and development of novel biopharmaceuticals generated by the broad biodiversity of cone snails.

The project aims at characterizing from the genomic up to potential therapeutic properties all the putative bioactive compounds that can be synthesised by a cone snail species. The genome and transcriptome of Conus consors will be exhaustively studied. Large amounts of venom will be fractionated and submitted to proteomic studies to generate a biochemically characterized 'natural library' of compounds. Large-scale synthesis of each identified candidate will be achieved to form a "synthetic library" of compounds.

Aufforderung zur Vorschlagseinreichung

FP6-2005-LIFESCIHEALTH-6
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

IP - Integrated Project

Koordinator

ATHERIS LABORATORIES, DR RETO STÖCKLIN
EU-Beitrag
Keine Daten
Adresse
Chemin d'Alcire 1
PLAN-LES-OUATES - GENEVA
Schweiz

Auf der Karte ansehen

Links
Gesamtkosten
Keine Daten

Beteiligte (19)